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Abstract
Background: Hospitalized patients with COVID-19 have increased risks of venous
(VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are
well-known risk factors; however, a risk assessment model (RAM) for VTE in patients
with both cancer and COVID-19 is lacking.
Objectives: To assess the incidence of and risk factors for thrombosis in hospitalized
patients with cancer and COVID-19.
Methods: Among patients with cancer in the COVID-19 and Cancer Consortium registry (CCC19) cohort study, we assessed the incidence of VTE and ATE within 90 days
of COVID-19–associated hospitalization. A multivariable logistic regression model
specifically for VTE was built using a priori determined clinical risk factors. A simplified RAM was derived and internally validated using bootstrap.
Results: From March 17, 2020 to November 30, 2020, 2804 hospitalized patients
were analyzed. The incidence of VTE and ATE was 7.6% and 3.9%, respectively. The
incidence of VTE, but not ATE, was higher in patients receiving recent anti-cancer
therapy. A simplified RAM for VTE was derived and named CoVID-TE (Cancer subtype
high to very-high risk by original Khorana score +1, VTE history +2, ICU admission
+2, D-dimer elevation +1, recent systemic anti-cancer Therapy +1, and non-Hispanic
Ethnicity +1). The RAM stratified patients into two cohorts (low-risk, 0–2 points,
n = 1423 vs. high-risk, 3+ points, n = 1034) where VTE occurred in 4.1% low-risk
and 11.3% high-risk patients (c statistic 0.67, 95% confidence interval 0.63–0.71). The
RAM performed similarly well in subgroups of patients not on anticoagulant prior to
admission and moderately ill patients not requiring direct ICU admission.
Conclusions: Hospitalized patients with cancer and COVID-19 have elevated thrombotic risks. The CoVID-TE RAM for VTE prediction may help real-time data-driven
decisions in this vulnerable population.
KEYWORDS

clinical decision rules, COVID-19, SARS-CoV-2, thrombosis, venous thromboembolism
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3

Essentials

Numerous studies have demonstrated a complex interplay between
inflammation and coagulation associated with COVID-19 that results
in an increased risk of venous thromboembolism (VTE) and arterial
thrombotic events (ATE).1–4 Specifically, the exact incidence of VTE
associated with COVID-19 is debated and has ranged from as low
as 1% in the general wards to as high as 69% in intensive care units
(ICUs) in published reports, depending on the diagnostic approach
used and whether screening was performed.5,6 The link between co-

• The exact risk for venous thromboembolism (VTE) in patients with cancer and COVID-19 is unknown.
• We assessed the VTE incidence and derived a risk assessment model (RAM) in the CCC19 consortium.
• Hospitalized patients with both active cancer and
COVID-19 have elevated risk of VTE (7.6%).
• A newly derived VTE RAM on admission (CoVID-TE) can
risk stratify patients (11.3% vs. 4.1%).

agulopathy and COVID-19 has led to an international collaborative
effort of randomized controlled studies designed to investigate the
use of anticoagulant therapy to prevent complications associated

data management is coordinated through REDCap at Vanderbilt

with COVID-19 among hospitalized medical inpatients, of which the

University. Given the de-identified nature of the data collected, this

interim unpublished results were recently released.7

study has been exempted from institutional review board (IRB) re-

Both cancer and anti-cancer therapies are well-known risk fac-

view at Vanderbilt University.

tors for thrombotic events.8,9 While many risk factors have been
identified for VTE in patients with cancer, advanced disease as well
as certain cancer types such as neoplasms of the pancreas, esoph-

2.2 | Cohort selection

agus, and stomach carry the highest risk.10,11 Moreover, patients
with cancer have a higher incidence of VTE compared to acutely ill
12,13

medical patients without cancer.

Adult patients with an active or previous diagnosis of cancer with

Despite being a well-known

a laboratory-confirmed SARS-CoV-2 test from March 17, 2020 to

phenotype for thrombosis, cancer diagnosis and anti-cancer therapy

November 30, 2020 were included in the current study. Patients

have not yet been identified as a strong risk factor for COVID-19–

were excluded if they did not reside within United States or Canada,

associated thrombosis and the exact thrombotic risk in hospitalized

did not have assessable thrombotic complication status within

patients with both cancer and COVID-19 remains unknown. In ad-

90 days (13 weeks), were never hospitalized at baseline, had poor

dition, patients with cancer not only have a higher risk of VTE but

data quality (quality score ≥5, typically due to very high levels of

also have a higher risk of bleeding on anticoagulation compared to

missingness),19 or had follow-up less than 30 days (interval between

14,15

patients without cancer.

A better understanding of the epide-

the COVID-19 diagnosis and the analysis data lock).

miology and risk factors of thrombosis in patients with cancer and
COVID-19 will also help researchers, clinicians, and policymakers to
place results from the beforementioned randomized controlled trials

2.3 | Outcome definitions

in a relevant context and help discuss appropriate thromboprophylaxis in more vulnerable patients.

The primary outcomes included VTE as defined by pulmonary embo-

The current study has two aims. First, we aim to estimate the

lism (PE), deep vein thrombosis (DVT), or thrombosis not otherwise

90-day incidence of VTE and ATE for patients with COVID-19 and

specified (NOS); and ATE as defined by myocardial infarction (MI) or

cancer requiring hospitalization, stratified by ICU status and active

ischemic stroke (CVA). Secondary outcomes included frequency of

cancer status. Second, we aim to derive a simple risk assessment

PE and/or DVT (excluding thrombosis NOS), PE only, or CVA only.

model (RAM) specifically for VTE at the time of hospital admission.

All thrombotic complications were captured as binary “yes/no” responses through retrospective chart review. The exact definition

2
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(imaging vs. clinical diagnosis, proximal vs. distal, symptomatic vs.

M E TH O D S

incidental) was left to the discretion of individual sites. Notably, superficial venous thrombosis (SVT) was captured separately and was

2.1 | Study design
The

COVID-19

and

Cancer

not included in any of the above definitions.
Consortium

registry

(CCC19;

NCT04354701) is an ongoing multi-center effort to assess the

2.4 | Prognostic risk factors

clinical-pathologic factors and disease course among patients with
COVID-19 and either a current or previous diagnosis of cancer.

Members of the thrombosis research working group within the

Details of the original study design and data capture have been re-

CCC19 defined important prognostic risk factors for VTE in hospi-

ported previously and are available publicly.16–18 Briefly, data were

talized medical patients with both cancer and COVID-19 using pre-

captured at baseline around the time of COVID-19 diagnosis and

viously published data from general medical inpatients, 20 patients

then at 30 days, 90 days, and 180 days after diagnosis. Centralized

with cancer,10 and patients with COVID-195 (Table S1 in supporting

4
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information). Specifically, the following clinical variables were chosen

c-statistic, for which optimism was calculated as the mean differ-

a priori at the time of admission as potentially important covariates

ence in c-statistic between the original and 1000 bootstrapped

based on plausibility and literature: age at COVID-19 diagnosis, sex,

resamples.

race/ethnicity, morbid obesity with body mass index (BMI) ≥35, his-

Several exploratory and sensitivity analyses were performed.

tory of VTE, cancer type VTE risk according to the original Khorana

First, the model was tested after exclusion of patients who were

Score,10 cancer status (active vs. previous), any recent anti-cancer

already receiving anticoagulation prior to admission. Second, the

systemic therapy within prior 3 months, antiplatelet medication prior

model was assessed in patients not requiring ICU admission at the

to admission, anticoagulant medication prior to admission, or severe

time of hospitalization. Third, it was expanded to explore the addi-

COVID-19 disease requiring direct ICU admission. Additional labora-

tive values of key laboratory values. Finally, we examined the im-

tory values at the time of admission were included in an exploratory

pact of the final RAM on overall bleeding (defined as major, clinically

analysis: white blood cell count, hemoglobin, platelet count, and D-

relevant non-major, or minor bleeding without other specification)

dimer. Of note, we chose pre-admission anticoagulant use instead

and 30-day mortality. Data analysis was performed in R 4.0.3 (R

post-admission prophylaxis/therapeutic use to enable the calcula-

Foundation for Statistical Computing).

tion of risk factors at the time of admission.

2.5 | Statistical methods

3
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3.1 | Cohort selection and patient characteristics

The cumulative incidence of VTE and ATE within 90 days after
COVID-19–associated admission was determined by the number

A total of 6344 patients were recorded in the CCC19 database be-

of reported VTE or ATE events from data forms within 13 weeks

tween March 17, 2020 and November 30, 2020. After exclusion,

of follow-up divided by the number of total available patients that

2804 patients with cancer and COVID-19 diagnosis who required

met the inclusion and exclusion criteria. The primary and second-

hospitalization at diagnosis with valid thrombotic outcomes cap-

ary outcomes were further estimated in pre-specified subgroups

tured were included in the current study (Figure 1). Among this hos-

(ICU vs. wards, recent systemic therapy vs. none). The incidence

pitalized cohort, 16% (n = 440) were admitted directly to the ICU

trend was also plotted over quarterly intervals for the year 2020.

and 81% (n = 2271) were initially admitted to non-ICU medical wards

As neither thrombotic nor mortality events had associated time

(3% had unknown status). The median follow-up was 42 days (in-

stamps to protect patient identity, we did not perform competing

terquartile range [IQR] 21–90). Unless death had occurred prior to

risk analyses.

follow-up time point assessment, approximately 83% patients had

To derive a prognostic RAM for VTE, we built a multivariable logistic regression model to assess the association between 90-day

the 30-day follow-up form completed and 62% patients had the 90-
day follow-up form completed.

VTE outcomes and baseline covariates. We included all pre-specified

The median age of patients was 70 (IQR 60–79) and 54%

clinical covariates in a single model. With the exception of age, all

(n = 1504) were male (Table 1). Racial/ethnic breakdown revealed

other covariates were categorical. Age was explored both as a con-

48% (n = 1351) non-Hispanic White patients, 25% (n = 689) non-

tinuous linear variable and cubic splines. Additionally, interaction

Hispanic Black patients, 13% (n = 368) Hispanic patients, and 12%

between age and other covariates was checked using the likelihood

(n = 345) other. Approximately 74% (n = 2079) had solid tumors, 48%

ratio test. Adjusted odds ratios (OR) and 95% confidence intervals

(n = 1342) had disease in remission, and 36% (n = 1021) received

(CI) for VTE and PE were estimated from the models. The relative

systemic anti-cancer therapy within the 3 months prior to COVID-19

strengths of each predictor within the model were assessed using

diagnosis. The distribution of cancer subtypes is shown in Table S2 in

the model chi-square statistic. Multiple imputation through 10 iter-

supporting information. Among them, 3% (n = 73) had very high-risk

ations with additive regression, bootstrapping, and predictive mean

VTE malignancy (pancreatic, esophageal, stomach), 23% (n = 641)

matching was used to impute missing/unknown data for all clinical

had high-risk VTE malignancy (lung, ovarian, kidney, bladder, testic-

variables with <5% missingness in the primary analysis or laboratory

ular, lymphoma), and 75% (n = 2090) had low-risk VTE malignancy

variables with <10% missingness in the sensitivity analysis.

(all others). Approximately 15% (n = 429) of patients were reported

To create a simplified RAM, we used the strongest predictors

to have morbid obesity. D-dimer was measured in 58% (n = 1623)

from the multivariable model and assigned simplified integer scores

of patients and a significant majority had abnormal value (n = 1376,

based on the ratio from the division of the covariate’s beta coeffi-

85%). Eleven percent of patients (n = 297) had prior history of

cient by the lowest beta coefficient. Only patients with non-missing

VTE, 21% (n = 584) were taking anticoagulants, and 34% (n = 949)

values in all predictor categories were included in this analysis. Final

were taking antiplatelets prior to COVID-19 diagnosis. During the

risk categories were created using the sum of individual integer

COVID-19 admission, 53% (n = 1473) received anticoagulation for

scores. The overall goodness-of-fit of all models was checked using

prophylaxis, 13% (n = 367) received anticoagulation for therapeu-

the Hosmer-Lemeshow (HL) test and calibration plot. Internally val-

tic reasons, 22% (n = 609) received no anticoagulation, and 13%

idated discrimination was performed using the optimism-corrected

(n = 355) had unknown status.

|
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F I G U R E 1 Patient selection for study inclusion and exclusion. This flow diagram indicates the inclusion and exclusion criteria for patient
selection for the current study using the CCC19 consortium. * Some patients had unknown ICU admission status. CCC19, COVID-19 and
Cancer Consortium registry; ICU, intensive care unit

TA B L E 1 Demographics and baseline characteristics for
hospitalized patients with cancer and COVID-19
Hospitalized
patients
Total number, N

2804

Age in years, median (IQR)

70 (60–79)

Male sex, % (N)

54% (1504)

Race/ethnicity, % (N)
White

48% (1351)

Black

25% (689)

Hispanic

13% (368)

Other

12% (345)

Unknown/missing

2% (51)

Cancer subtype, % (N)a
Solid

74% (2079)

Hematologic

24% (676)

Other

2% (49)

Cancer status, % (N)
Remission/no evidence of disease

48% (1342)

Active, stable or responding

26% (742)

Active, progressing or unknown

23% (651)

Unknown/missing

2% (69)

Cancer staging, % (N)
Localized

50% (1405)

Disseminated

29% (812)

Unknown/missing

21% (587)

Recent systemic therapy last 3 months, % (N)
No

61% (1717)

Yes

36% (1021)

(Continues)

TA B L E 1 (Continued)
Hospitalized
patients
Unknown/missing

2% (66)

VTE risk by cancer subtype, % (N) b
Low-risk VTE malignancy

75% (2090)

High-risk VTE malignancy

23% (641)

Very high-risk VTE malignancy

3% (73)

History of VTE, % (N)
No

89% (2488)

Yes

11% (297)

Unknown/missing

1% (19)

Morbid obesity (BMI>35), % (N)
No

84% (2359)

Yes

15% (429)

Unknown/missing

1% (16)

Anticoagulant use prior to admission, % (N)
No

76% (2136)

Yes

21% (584)

Unknown/missing

3% (84)

Antiplatelet use prior to admission, % (N)
No

63% (1761)

Yes

34% (949)

Unknown/missing

3% (84)

Direct ICU admission, % (N)
No

81% (2271)

Yes

16% (440)

Unknown/missing

3% (93)

White blood cell (WBC), % (N)

(Continues)
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TA B L E 1 (Continued)

incidence remained nearly constant from the second to the fourth
quarter of 2020 (Figure S1 in supporting information).

Hospitalized
patients
Within normal limit of normal

58% (1614)

Below lower limit of normal

20% (552)

Above higher limit of normal

17% (468)

Unknown/missing

10% (173)

In the prespecified subgroup analysis (Table 2), the incidence of
all thrombotic complications was approximately 2-fold higher among
severely ill patients requiring direct ICU admission (VTE 14.1%, ATE
7.3%) compared to moderately ill patients requiring wards admission
(VTE 6.3%, ATE 3.2%). The incidence of VTE but not ATE was higher
among patients receiving recent anti-cancer systemic therapy (VTE

Hemoglobin (Hb), % (N)

10.0%, ATE 3.1%) compared to those not receiving recent therapy

Within normal limit of normal

37% (1034)

(VTE 5.8%, ATE 4.0%). There was no significant interaction between

Below lower limit of normal

55% (1552)

the two subgroups and the risk factors appeared to be multiplicative.

Above higher limit of normal

2% (45)

Unknown/missing

6% (173)

3.3 | Multivariable modeling of VTE and PE
risk among hospitalized patients with cancer and
COVID-19

Platelet (Plt), % (N)
Within normal limit of normal

61% (1709)

Below lower limit of normal

27% (757)

Above higher limit of normal

4% (125)

Unknown/missing

8% (213)

Variables significantly associated with VTE (primary outcome)
included recent anti-cancer systemic therapy (OR 1.58, 95% CI

D-dimer (DD), % (N)

1.16–2.14), VTE history (OR 1.89, 95% CI 1.21–2.95), and direct

Within normal limit of normal

9% (247)

Above higher limit of normal

49% (1376)

significant but appreciable variables with notable degrees of asso-

Not tested/not available

37% (1034)

ciation based on model chi-square test (Figure 3) included cancer

Unknown/missing

5% (147)

subtype VTE risk (OR 1.37, 95% CI 0.99–1.89 for high risk vs. low

ICU admission (OR 2.62, 95% CI 1.89–3.64; Figure 2). Other non-

risk; OR 1.74, 95% CI 0.83–3.64 for very-high risk vs. low risk) and

Abbreviations: BMI, body mass index; ICU, intensive care unit; IQR,

Hispanic race/ethnicity (OR 0.64, 95% CI 0.39–1.03 for Hispanic vs.
White). In the current study, Black patients represented 25% of the

3.2 | Incidence of VTE and ATE by illness
severity and systemic therapy subgroups

population but did not have an appreciably increased VTE risk compared to White patients (OR 0.99, 95% CI 0.70–1.40). The c statistic
was 0.67 (bootstrapped 95% CI 0.63–0.70). The model had adequate

Among hospitalized patients, VTE occurred in 7.6% (n = 213) pa-

fit as demonstrated by an HL test P-value of .48 and the appearance

tients, of which 4.0% (n = 113) were PE; ATE occurred in 3.9%

of the calibration plot (Figure S2 in supporting information).

(n = 109) patients, of which 1.6% (n = 45) were CVA. Most VTE

The multivariable model for PE (secondary outcome) showed a

and ATE events occurred within 30 days of hospitalization. The

similar pattern of associations (Table S3 in supporting information).

TA B L E 2 Incidence of venous thrombosis (VTE, PE/DVT, PE) and arterial thrombosis (ATE, CVA) in cancer patients within 90 days post-
SARS-CoV-2 diagnosis and hospitalization, stratified by ICU admission & anti-cancer treatment
VTE

PE/DVT

PE

ATE

CVA

7.6% (213)

6.6% (186)

4.0% (113)

3.9% (109)

1.6% (45)

Direct ICU admission (n = 440)

14.1% (62)

12.3% (54)

7.5% (33)

7.3% (32)

2.3% (10)

Wards admission (n = 2271)

6.3% (143)

5.5% (126)

3.3% (75)

3.2% (72)

1.4% (31)

Recent systemic therapy (n = 1021)

10.0% (102)

8.9% (91)

5.7% (58)

3.1% (32)

1.4% (14)

No recent therapy (n = 1717)

5.8% (99)

4.8% (83)

2.6% (45)

4.0% (69)

1.7% (29)

Hospitalized patients with cancer and
COVID (n = 2804)
ICU admission statusa

Recent anti-cancer therapyb

Note: VTE = venous thromboembolism defined as pulmonary embolism (PE), deep vein thrombosis (DVT), or thrombosis not otherwise specified (i.e.,
unusual splanchnic or cerebral sinus venous thrombosis), ATE = arterial thromboembolism defined as myocardial infarction or ischemic stroke (CVA).
Abbreviation: ICU, intensive care unit.
a

There are 93 patients with unknown/missing ICU admission status.

b

There are 66 patients with unknown/missing recent anti-c ancer status.
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F I G U R E 2 Forest plot for multivariable logistic regression analysis for association between potential clinical variables and venous
thromboembolism (VTE) and pulmonary embolism (PE; n = 2804). This forest plot shows the adjusted odds ratios (OR) for either VTE or PE
for each of the chosen clinical covariates. * Adapted from Khorana Score: very-high risk = pancreas, stomach, esophageal; high risk: lung,
ovarian, kidney, bladder, testicular, lymphoma

F I G U R E 3 Relative importance of variables in the predictive model. This figure shows the relative strengths of each predictor within the
final multivariable model assessed via the model chi-square statistics. VTE, venous thromboembolism

The additional variable that reached significant association was anticoagulant use prior to admission (OR 0.40, 95% CI 0.22–0.75). The

3.4 | Scenario and sensitivity analyses for
VTE predictors

PE-specific model had similar performance as the VTE model with a
discrimination c statistic of 0.69 (bootstrapped 95% CI 0.64–0.74)

We performed several additional scenario and sensitivity analyses. In

and an HL P-value of .13. Dedicated association testing for ATE out-

the scenarios in which we retested the clinical model after excluding

comes was not performed due to the low number of events.

patients on anticoagulants prior to admission (Table S4 in supporting

8
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TA B L E 3 Simplified risk assessment model for VTE (CoVID-TE
thromboembolism score) in hospitalized patients with complete
data. (a) CoVID-TE score assignment, (b) CoVID-TE risk category
stratification and performance

2804 patients, 2457 had complete data capture for all the chosen
baseline variables (no imputation). Variables with their associated
weights included: Cancer subtype high to very-high risk by original

Risk assesment model

Khorana score (pancreas, stomach, esophageal, lung, ovarian, kid-

(a)

ney, bladder, testicular, lymphoma; +1), VTE history (+2), ICU admission (+2), D-dimer elevated on admission (+1), Therapy (recent

Baseline variables

Point

Cancer subtype by original Khorana scorea

+1

VTE history (lifetime)

+2

ICU triage on admission

+2

D-dimer elevatedb

+1

Therapy (recent systemic last 3 months)

+1

Ethnicity non-Hispanicc

3 or higher (n = 1034) had appreciably increased risk of VTE (11.3%)

+1

and PE (5.5%). The simplified RAM had modest discrimination with

systemic therapy last 3 months) (+1), and Ethnicity non-Hispanic (+1;
Table 3). The initial letter of each variable formed the new risk assessment model “CoVID-TE” for COVID-19–associated thromboembolism. Patients with scores 0 to 2 (n = 1423) appeared to have lower
risk of VTE (4.1%) and PE (2.3%). In contrast, patients with a score of

(b)

a c statistic of 0.67 (0.63–0.71) for VTE prediction and an HL test

All hospitalized patients (n = 2457)

anticoagulant use prior to COVID-19 diagnosis, the CoVID-TE RAM

Risk category (N)

VTE % (N)

P-value of .90. In a sensitivity analysis, after excluding patients with
PE % (N)

Low-risk (0–2)

4.1% (59)

2.3% (33)

0–1 (657)

3.6% (24)

2.0% (13)

2 (766)

4.6% (35)

2.6% (20)

11.3% (117)

5.5% (57)

3 (529)

8.9% (47)

3.6% (19)

4 (317)

11.7% (37)

6.3% (20)

5+ (188)

17.6% (33)

9.6% (18)

High-risk (3+)

C statistic (95% CI)
HL test p-value

0.67 (0.63–0.71)

demonstrated similar discrimination, with a c-statistic of 0.69 (0.64–
0.74) for VTE prediction (Table S7 in supporting information). Finally,
we assessed overall bleeding and 30-day mortality for patients
stratified by the CoVID-TE RAM (Table S8 in supporting information). Compared to patients with low risk for VTE, those classified as
high risk for VTE also had higher risk for overall bleeding (10.0% vs.
4.3%) and mortality (29.3% vs. 19.5%). As the bleeding endpoint was
not predefined or adjudicated, this remained an exploratory analysis.

0.67 (0.61–0.73)

.90

.77

Note: Integer points (1 or 2 points) were assigned to each of the baseline
variables listed in the table above. A final composite score ranging from 0
to 8 is created. Based on outcome distribution shown above, 0–2 point is
considered low-risk and 3 or more points is considered high-risk.
Abbreviations: HL, Hosmer-Lemeshow test; ICU, intensive care unit; PE,
pulmonary embolism; VTE, venous thromboembolism.
a

Combined high and very-high risk categories based on the original
Khorana score: pancreas, stomach, esophageal, lung, ovarian, kidney,
bladder, testicular, lymphoma.

b

proportional to the beta coefficients. From the original cohort of

Specific cut-off could not be determined using the current dataset.

c

Asian race also associated with lower risk of VTE in other studies;
however, this was not specifically assessed in the current study.

4

|

DISCUSSION

In this retrospective cohort study of 2804 hospitalized patients with
COVID-19 and cancer, we found the 90-day VTE and ATE incidences
were elevated at 7.6% (n = 213) and 3.9% (n = 109), respectively.
VTE risk was higher in patients admitted to ICU and those with active cancer having received recent systemic therapy. Our newly derived VTE risk assessment model, the CoVID-TE score, incorporated
six clinicopathologic factors readily available at the time of hospital
admission. With a modest discrimination, the CoVID-TE score stratified patients into two different risk categories: 58% in the low-risk
group (score 0–2) had an observed incidence of 4.1% for VTE and
2.3% for PE; 42% in the high-risk group (score 3+) had an incidence

information) or excluding severely ill patients requiring ICU admis-

of 11.3% for VTE and 5.5% for PE. Patients with these thrombotic

sion (Table S5 in supporting information), the models retained very

risk factors might also be at higher risk for bleeding and mortality.

similar magnitude and significance for its list of associated factors.

We believe risk stratification from the current study can provide rel-

In a separate sensitivity analysis after adding laboratory values to

evant context and help with the interpretation and implementation

the clinical model, elevated D-dimer and platelet count were signifi-

of anticoagulant prophylaxis based on the results of ongoing rand-

cantly associated with VTE, but the overall c-statistic was not appre-

omized controlled trials for this vulnerable patient population.

ciably different (Table S6 in supporting information).

While COVID-19, prolonged hospitalization, and active cancer
are all well-known pro-thrombotic risk factors, the exact incidence

3.5 | CoVID-TE simplified risk assessment score

of thrombosis in a population with all three has not been previously
reported. We examined the incidence over a 90-day follow-up to
match with previous studies for medical inpatient-associated throm-

Based on the key predictors from the multivariable model, we cre-

bosis.20 Among general patients hospitalized with COVID-19, the

ated a simplified prediction score by assigning integer weights

reported incidence based on retrospective cohort studies varies

|
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significantly depending on the geographic region, acute care setting,
anticoagulation preference, and study outcome definitions.

21

Within

the United States, the reported incidence of VTE ranges from 1% to

9

risk prediction tool could provide the initial rationale for a risk modeling approach to exploring the THE that is inevitable in a trial of
patients with COVID-19.

4% and ATE (excluding biomarker-only definition of MI similar to our

There are several strengths and limitations to our study. Our

study) ranges from 1% to 2% for patients admitted to the wards.22–25

study was one of the largest series from more than 128 institutions to

In contrast, those admitted to the ICU have a reported incidence of

examine the thrombotic complications among hospitalized patients

VTE ranging from 8% to 14% and ATE ranging from 6% to 8%.22–26

with cancer and COVID-19. Due to the sample size, we were able to

In the current study, we observed a similar incidence of hospital-

apply stringent selection criteria to ensure adequate follow-up and

associated thrombosis (VTE 4.5% in wards, 12.2% in ICU; ATE 3.2%

exclude patients with incomplete data capture such that multiple

in wards, 8.1% in ICU) in patients with history of cancer but not on

imputation was only performed to address missing data in variables

active therapy (many of whom were in remission or had no current

with <5% missingness (or <10% in exploratory analyses). Our mul-

evidence of cancer). This finding suggests that a historical diagnosis

tiple sensitivity analyses showed that the findings would be repli-

of cancer alone may not be a significant risk factor for thrombosis. In

cable under different meaningful clinical scenarios. Furthermore,

contrast, patients with cancer and COVID-19 recently receiving sys-

the CoVID-TE RAM consists of variables that are simple and readily

temic therapy had significantly higher than expected incidence for

available to providers at the time of admission with the potential to

VTE (9.0% in wards, 15.8% in ICU) but not ATE (2.7% in wards, 4.8%

impact the care of patients with cancer and COVID-19 in a meaning-

in ICU). The additive effects from active infection and active anti-

ful way. Limitations inherent to our non-randomized retrospective

cancer treatment may cause these patients to be at particularly high

study nature include the potential for unmeasured confounding, se-

risk for hospital-associated VTE. Of note, we excluded patients not

lection bias, and underreporting of outcomes. Given that each in-

requiring hospitalization at the time of COVID-19 diagnosis as their

stitution had its own protocol for the prevention and diagnosis of

information might not be fully captured and their outcomes might

thrombosis, this heterogeneity could have impacted the actual rates

be under-reported. Nonetheless, we observed very low thrombotic

from individual sites, although the stable aggregate rates of VTE over

rates with 0.7% VTE and 0.2% ATE at the same 90-day follow-up

each quarter of 2020 verified overall consistency. Furthermore, the

window among outpatients in the CCC19 registry (excluded from

heterogeneous use of anticoagulation before admission (21%) and

this study).

the low proportion of very high-risk cancer types (3%) may limit the

In addition to reporting the incidence of thrombosis, the high-

generalizability of the RAM. Additionally, we did not perform time-

light of the current work is the derivation of a parsimonious RAM

to-event or competing risks analysis due to the lack of specific timing

using the six important clinical variables. To facilitate ease of use,

for VTE complications. Finally, for any novel model to be clinically

we focused on simplicity and availability at presentation to the

applicable, it needs to be tested and validated in an external cohort.

hospital. Consistent with previously published data outside of the

In conclusion, we investigated the incidence of venous and arte-

COVID-19 literature, we found that ICU admission, recent systemic

rial thromboses in hospitalized patients with cancer and COVID-19

therapy, history of VTE, cancer VTE risk subtype, non-Hispanic

and derived a new RAM that can be calculated at the time of admis-

race/ethnicity, and active cancer status were the strongest clini-

sion to risk stratify patients into different VTE risk groups. We antic-

cal risk factors associated with VTE. Among the laboratory-b ased

ipate that the CoVID-TE RAM, upon external validation, can serve as

variables, both thrombocytosis and elevated D-dimer were as-

a real-time clinical decision support tool to assist with personalized

sociated with increased VTE. We chose to use D-dimer, as it is

decisions on the initiation of thromboprophylaxis in hospitalized pa-

now more commonly measured in the hospitalized patient with

tients with cancer and COVID-19.

COVID-19

27

and when assessed prior to the pandemic, it was spe-

cifically superior to thrombocytosis as a biomarker for VTE risk
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prediction. 28
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